Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B

NCT01488994 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01488994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01488994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B
Lead sponsor
Baxalta now part of Shire
Phase
Phase 2/3
Overall status
Completed
Start date
December 20, 2011
Completion date
May 14, 2013
Enrollment
23 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b